The neurologist
Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod: A Case Report.
Zhouao Zhang, Xinyan Guo, Tiancheng Luo, Mingjin Yang, Tianyu Ma, Xue Du, Zhouyi Wang, Xiaoyu Huang, Yong Zhang
Published: 202610.1097/NRL.0000000000000651
Abstract
INTRODUCTION: Myasthenic crisis (MC) is the most serious manifestation of myasthenia gravis (MG) and it poses a big challenge in clinical management. Plasma exchange and intravenous immunoglobulin are the first-line therapy for MC, but a subset of pa…
Preview only. Read the full abstract at the source